{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:41:49Z","timestamp":1788309709709,"version":"build-2803163510"},"reference-count":191,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.berh.2024.101976","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:12:16Z","timestamp":1724418736000},"page":"101976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-353X","authenticated-orcid":false,"given":"Saskia R.","family":"Veldkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"van Royen-Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc HA.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0000000000000224","article-title":"Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes","volume":"27","author":"Tansley","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2024.101976_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152104","article-title":"The clinical features of juvenile dermatomyositis: a single-centre inception cohort","volume":"57","author":"Cancarini","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11926-005-0048-1","article-title":"Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?","volume":"7","author":"Huber","year":"2005","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/rheumatology\/keq261","volume":"50","author":"Martin","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12969-016-0118-0","article-title":"Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study","volume":"14","author":"Okong\u2019o","year":"2016","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1756-185X.13759","article-title":"Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India","volume":"23","author":"Sharma","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.rdc.2021.07.003","article-title":"Updates on juvenile dermatomyositis from the last decade: classification to outcomes","volume":"47","author":"Kim","year":"2021","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1756-185X.12107","article-title":"Clinical features and disease course of patients with juvenile dermatomyositis","volume":"16","author":"Gowdie","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s10067-014-2675-2","article-title":"Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis","volume":"33","author":"Malek","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib15","first-page":"782","article-title":"Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients","volume":"28","author":"Mathiesen","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-\u03b1\/\u03b2\u2013mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib18","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of Pathogenesis1","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.berh.2024.101976_bib22","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon\u2013regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Gene Immun"},{"key":"10.1016\/j.berh.2024.101976_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606874","article-title":"Context is key: delineating the unique functions of IFN\u03b1 and IFN\u03b2 in disease","volume":"11","author":"Fox","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib25","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib26","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2024.101976_bib27","author":"Moreau"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","article-title":"Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis","volume":"63","author":"Covert","year":"2024","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib30","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib31","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","article-title":"Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-\u03b1 signalling","volume":"59","author":"Melki","year":"2020","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/rheumatology\/key386","article-title":"The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients","volume":"58","author":"Ono","year":"2019","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib33","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1093\/rheumatology\/kead165","article-title":"In-depth proteomic analysis of juvenile dermatomyositis serum reveals protein expression associated with muscle-specific autoantibodies","volume":"62","author":"Sato","year":"2023","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib35","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib36","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.41615","article-title":"Comparison of lesional juvenile myositis and lupus skin reveals overlapping yet unique disease pathophysiology","volume":"73","author":"Turnier","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib37","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib38","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jid.2020.12.032","article-title":"Myeloid dendritic cells are major producers of IFN-\u03b2 in dermatomyositis and may contribute to hydroxychloroquine refractoriness","volume":"141","author":"Chen","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.berh.2024.101976_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00281","article-title":"Aberrant type I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology","volume":"4","author":"Reder","year":"2013","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/acr2.11081","article-title":"Gene expression meta-analysis reveals concordance in gene activation, pathway, and cell-type enrichment in dermatomyositis target tissues","volume":"1","author":"Neely","year":"2019","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/cvr\/cvn029","article-title":"Understanding the immunoangiostatic CXC chemokine network","volume":"78","author":"Balestrieri","year":"2008","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib43","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/art.21303","article-title":"Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy","volume":"52","author":"Fall","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib44","first-page":"e56","article-title":"The CXCR3 chemokines in inflammatory myopathies","volume":"166","author":"Limongi","year":"2015","journal-title":"Clin Ter"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","article-title":"Type I interferon\u2010associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis","volume":"31","author":"Wenzel","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103420","article-title":"IFN-\u0393: an overlooked cytokine in dermatomyositis with anti-MDA5 antibodies","volume":"22","author":"Thuner","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib48","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"S1","key":"10.1016\/j.berh.2024.101976_bib49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.410370709","article-title":"Immunopathogenesis of inflammatory myopathies","volume":"37","author":"Dalakas","year":"1995","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.berh.2024.101976_bib51","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1002\/art.34606","article-title":"Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib52","first-page":"605","article-title":"MHC Class I overexpression on muscles in early juvenile dermatomyositis","volume":"31","author":"Li","year":"2004","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib53","doi-asserted-by":"crossref","first-page":"885","DOI":"10.6061\/clinics\/2012(08)05","article-title":"Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis","volume":"67","author":"Shinjo","year":"2012","journal-title":"Clinics"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib54","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.21103","article-title":"Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction","volume":"52","author":"Nagaraju","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"24","key":"10.1016\/j.berh.2024.101976_bib55","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1111\/jcmm.17621","article-title":"Major histocompatibility complex I-induced endoplasmic reticulum stress mediates the secretion of pro-inflammatory muscle-derived cytokines","volume":"26","author":"Thoma","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib56","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.22558","article-title":"Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis","volume":"56","author":"L\u00f3pez de Padilla","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0022-510X(90)90156-H","article-title":"Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy","volume":"99","author":"McDouall","year":"1990","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00296-020-04735-w","article-title":"Inflammatory milieu of muscle biopsies in juvenile dermatomyositis","volume":"41","author":"Sag","year":"2021","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib60","first-page":"470","article-title":"Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis","volume":"55","author":"Gitiaux","year":"2016","journal-title":"Rheumatology"},{"issue":"21","key":"10.1016\/j.berh.2024.101976_bib61","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.berh.2024.101976_bib62","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1212\/WNL.0000000000200679","article-title":"Type I interferons in dermatomyositis myoblasts","volume":"98","author":"Pinal-Fernandez","year":"2022","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib63","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib64","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2014-206287","article-title":"Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity","volume":"74","author":"Bellutti Enders","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib65","first-page":"753","article-title":"Juvenile dermatomyositis: histological findings and pathogenetic hypothesis for the associated skin changes","volume":"13","author":"Bowyer","year":"1986","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/art.1780250203","article-title":"Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis","volume":"25","author":"Crowe","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2133.2008.08967.x","article-title":"Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle","volume":"160","author":"Greenberg","year":"2009","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197202172860701","article-title":"Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy","volume":"286","author":"Whitaker","year":"1972","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.berh.2024.101976_bib70","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.WNL.0000291619.17160.b8","article-title":"Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications","volume":"69","author":"Greenberg","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib71","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib72","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2016.12.68","article-title":"Vascular changes and perifascicular muscle fiber damage in dermatomyositis: another question of the chicken or the egg that is on our mind","volume":"5","author":"Paepe","year":"2017","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib73","first-page":"801","article-title":"Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis","volume":"31","author":"Sallum","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2024.101976_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.827786","article-title":"T cell interaction with activated endothelial cells primes for tissue-residency","volume":"13","author":"Wienke","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib75","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/art.22993","article-title":"Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients","volume":"57","author":"Miles","year":"2007","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.23299","article-title":"Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis","volume":"58","author":"Christen-Zaech","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib77","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12969-023-00919-3","article-title":"Juvenile dermatomyositis: association between nail fold capillary end row loop\u2013 area under the curve\u2013 and disease damage indicators","volume":"21","author":"Khojah","year":"2023","journal-title":"Pediatr Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib78","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/rheumatology\/keq407","article-title":"Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis","volume":"50","author":"Schmeling","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib79","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.23341","article-title":"Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis","volume":"59","author":"Rouster-Stevens","year":"2008","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib80","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/rheumatology\/keab520","article-title":"Metabolomics analysis identifies a lipidomic profile in treatment-na\u00efve juvenile dermatomyositis patients vs healthy control subjects","volume":"61","author":"Dvergsten","year":"2022","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib81","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jpeds.2011.05.015","article-title":"Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis","volume":"159","author":"Eimer","year":"2011","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.berh.2024.101976_bib82","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3899\/jrheum.090061","article-title":"Arterial events in persons with dermatomyositis and polymyositis","volume":"36","author":"Tisseverasinghe","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/rheumatology\/keaa270","article-title":"Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk","volume":"60","author":"Wienke","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2024.101976_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01601","article-title":"Self-DNA at the epicenter of SLE: immunogenic forms, regulation, and effects","volume":"10","author":"Soni","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib85","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1084\/jem.20151876","article-title":"Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus","volume":"213","author":"Caielli","year":"2016","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib86","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41423-023-01086-x","article-title":"Mitochondrial DNA-triggered innate immune response: mechanisms and diseases","volume":"20","author":"Hu","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib87","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib88","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.41078","article-title":"Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis","volume":"72","author":"Duvvuri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2024.101976_bib89","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead654","article-title":"The emerging role of growth differentiation factor 15 as a potential disease biomarker in juvenile dermatomyositis","author":"Duvvuri","year":"2023","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib90","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard-2022-223469","article-title":"Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis","volume":"82","author":"Wilkinson","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2024.101976_bib91","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.8611","article-title":"Co-expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis","volume":"8","author":"Zhong","year":"2020","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib92","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","article-title":"IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis","volume":"134","author":"Meyer","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib93","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib94","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/nan.12528","article-title":"Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features","volume":"45","author":"Yasin","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.berh.2024.101976_bib95","article-title":"Pathogenic autoantibody internalization in myositis","volume":"2024","author":"Pinal-Fernandez","year":"2024","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","article-title":"The expression of BAFF in the muscles of patients with dermatomyositis","volume":"249","author":"Baek","year":"2012","journal-title":"J Neuroimmunol"},{"issue":"16","key":"10.1016\/j.berh.2024.101976_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13162626","article-title":"B cell lymphocytosis in juvenile dermatomyositis","volume":"13","author":"Costin","year":"2023","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14336\/AD.2020.0410","article-title":"The role of immune cells in the pathogenesis of idiopathic inflammatory myopathies","volume":"12","author":"Zhao","year":"2021","journal-title":"Aging Dis"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib99","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.berh.2024.101976_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-\u03b1","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2024.101976_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.902232","article-title":"Multi-modal single-cell sequencing identifies cellular immunophenotypes associated with juvenile dermatomyositis disease activity","volume":"13","author":"Neely","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2024.101976_bib102","article-title":"Coordinated immune dysregulation in Juvenile Dermatomyositis revealed by single-cell genomics","volume":"2023","author":"Rabadam","year":"2023","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib103","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/art.42446","article-title":"Association of juvenile dermatomyositis disease activity with the expansion of blood memory B and T cell subsets lacking follicular markers","volume":"75","author":"Gofshteyn","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib104","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","article-title":"A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate","volume":"25","author":"Caielli","year":"2019","journal-title":"Nat Med"},{"issue":"7639","key":"10.1016\/j.berh.2024.101976_bib105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib106","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib107","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib108","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib109","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/ket279","article-title":"Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy","volume":"53","author":"Venalis","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5+CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib111","first-page":"194","article-title":"Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies","volume":"59","author":"Wilkinson","year":"2020","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib112","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/glycob\/cwad005","article-title":"Sialylation-dependent interaction between PD-L1 and CD169 promotes monocyte adhesion to endothelial cells","volume":"33","author":"Cai","year":"2023","journal-title":"Glycobiology"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib114","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/art.42283","article-title":"Imaging mass cytometry reveals predominant innate immune signature and endothelial\u2013immune cell interaction in juvenile myositis compared to lupus skin","volume":"74","author":"Turnier","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"issue":"22","key":"10.1016\/j.berh.2024.101976_bib116","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123236","article-title":"Dysregulated NK cell PLC\u03b32 signaling and activity in juvenile dermatomyositis","volume":"3","author":"Throm","year":"2018","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.berh.2024.101976_bib117","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib118","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11926-996-0007-5","article-title":"Juvenile dermatomyositis: the association of the TNF\u03b1-308A Allele and disease chronicity","volume":"3","author":"Pachman","year":"2001","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib119","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-016-3467-6","article-title":"Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome","volume":"36","author":"Saini","year":"2016","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.berh.2024.101976_bib120","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1002\/art.23960","article-title":"Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features","volume":"58","author":"Stringer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib121","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib122","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41598-021-04302-8","article-title":"Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive","volume":"12","author":"Roberson","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib123","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib125","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/acr2.11618","article-title":"Type 1 interferon-stimulated gene expression and disease activity in pediatric rheumatic diseases: No composite scores needed?","volume":"5","author":"Weiden","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/adc.69.2.232","article-title":"Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis","volume":"69","author":"De Benedetti","year":"1993","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12010008","article-title":"Clues to disease activity in juvenile dermatomyositis: neopterin and other biomarkers","volume":"12","author":"Khojah","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1442-200x.2001.01367.x","article-title":"Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis","volume":"43","author":"Kobayashi","year":"2001","journal-title":"Pediatr Int"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib129","first-page":"1681","article-title":"Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies","volume":"48","author":"Rider","year":"2002","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib131","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/art.41236","article-title":"Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two independent cohorts of patients with juvenile dermatomyositis","volume":"72","author":"Wienke","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib132","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/art.24803","article-title":"Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib133","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2024.101976_bib134","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/kex220","article-title":"Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study","volume":"56","author":"Rose","year":"2017","journal-title":"Rheumatology"},{"issue":"14","key":"10.1016\/j.berh.2024.101976_bib135","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1177\/0961203320965699","article-title":"SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus","volume":"29","author":"Stuckrad","year":"2020","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib136","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"Rodr\u00edguez-Carrio","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2024.101976_bib137","author":"Medisch Specialisten"},{"issue":"10","key":"10.1016\/j.berh.2024.101976_bib138","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2024.101976_bib139","article-title":"Aberrantly expressed galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease","volume":"9","author":"Liang","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib140","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jpeds.2010.04.034","article-title":"Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis","volume":"157","author":"Niewold","year":"2010","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib141","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/rheumatology\/keaa497","article-title":"Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models","volume":"60","author":"Deakin","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2024.101976_bib142","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae027","article-title":"Disease activity trajectories in juvenile dermatomyositis from childhood to adulthood","author":"Nozawa","year":"2024","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020552","article-title":"The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score","volume":"11","author":"Gibbs","year":"2023","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib144","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3899\/jrheum.181275","article-title":"Endothelial activation markers as disease activity and damage measures in juvenile dermatomyositis","volume":"47","author":"Kishi","year":"2020","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib145","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/art.41639","article-title":"The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness","volume":"73","author":"Papadopoulou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2024.101976_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103061","article-title":"Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis","volume":"138","author":"Duvvuri","year":"2023","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib147","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148709","article-title":"GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction","volume":"11","author":"Montero","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2024.101976_bib148","article-title":"Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis","author":"Floranne","year":"2013","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib149","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0000000000000831","article-title":"Lymphocyte immunophenotyping in inflammatory myositis: a review","volume":"33","author":"Franco","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/cdli.2.2.205-208.1995","article-title":"Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis","volume":"2","author":"O'Gorman","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"10019","key":"10.1016\/j.berh.2024.101976_bib151","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib152","doi-asserted-by":"crossref","first-page":"457","DOI":"10.55563\/clinexprheumatol\/ltrj4l","article-title":"A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine","volume":"40","author":"Marrani","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2024.101976_bib153","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae096","article-title":"Where are we now in biologic drugs for myositis?","author":"Neves","year":"2024","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib154","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children's arthritis and Rheumatology research alliance consensus conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib155","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and Rheumatology research alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib156","doi-asserted-by":"crossref","first-page":"394","DOI":"10.55563\/clinexprheumatol\/56ilob","article-title":"Juvenile dermatomyositis. Where are we now?","volume":"40","author":"McCann","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib157","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-018-0257-6","article-title":"Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib158","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib159","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cpdd.887","article-title":"Safety, tolerability, and pharmacokinetics of PF-06823859, an anti\u2013interferon \u03b2 monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study","volume":"10","author":"Neelakantan","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2024.101976_bib160","first-page":"936","article-title":"POS1207 efficacy and safety of anti-IFN\u0392-specific monoclonal antibody, PF-06823859, on myositis: phase 2 study in patients with moderate-to-severe dermatomyositis","volume":"82","author":"Aggarwal","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2024.101976_bib161","series-title":"[abstract] ACR Convergence 2023","article-title":"Rapid onset of response in adult dermatomyositis patients receiving anti-interferon \u03b2 (PF-06823859): results of a phase 2, double-blind, randomized, placebo-controlled study","author":"Aggarwal","year":"2023"},{"issue":"5","key":"10.1016\/j.berh.2024.101976_bib162","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib163","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10067-023-06567-y","article-title":"Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis","volume":"42","author":"Wang","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib164","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2024.101976_bib165","first-page":"1","article-title":"Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis","author":"Kim","year":"2024","journal-title":"Expet Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib167","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/ar4212","article-title":"Cardiovascular risk in pediatric-onset rheumatological diseases","volume":"15","author":"Barsalou","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib168","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2024.101976_bib169","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2019.02.027","article-title":"Tracking changes in nailfold capillaries during dermatomyositis treatment","volume":"81","author":"Argobi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2024.101976_bib171","doi-asserted-by":"crossref","first-page":"s256","DOI":"10.1007\/s10072-003-0090-6","article-title":"High-dose intravenous immunoglobulinin inflammatory myopathies: experience based on controlledclinical trials","volume":"24","author":"Dalakas","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.berh.2024.101976_bib172","series-title":"A pilot study of eculizumab in patients with dermatomyositis. Arthritis and Rheumatism","first-page":"605","year":"2002"},{"issue":"12","key":"10.1016\/j.berh.2024.101976_bib173","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jamadermatol.2022.3917","article-title":"Apremilast in recalcitrant cutaneous dermatomyositis: a nonrandomized controlled trial","volume":"158","author":"Bitar","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"23","key":"10.1016\/j.berh.2024.101976_bib174","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242317017","article-title":"PDE4 phosphodiesterases in cardiovascular diseases: key pathophysiological players and potential therapeutic targets","volume":"24","author":"Puertas-Umbert","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2024.101976_bib175","series-title":"Key processes in cardiovascular disease. [abstract] ACR\/ARP annual meeting","article-title":"PDE4 inhibition could improve endothelial and adipose tissue dysfunction associated with psoriatic arthritis","author":"Arias de la Rosa","year":"2019"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib176","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13063-023-07083-9","article-title":"Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study","volume":"24","author":"Abbasifard","year":"2023","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib178","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaad.2020.12.032","article-title":"Skin disease is more recalcitrant than muscle disease: a long-term prospective study of 184 children with juvenile dermatomyositis","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2024.101976_bib179","author":"Arena"},{"key":"10.1016\/j.berh.2024.101976_bib180","article-title":"Therapeutic development by targeting the cGAS-STING pathway in autoimmune disease and cancer","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib181","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib182","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"issue":"24","key":"10.1016\/j.berh.2024.101976_bib183","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"10416","key":"10.1016\/j.berh.2024.101976_bib184","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082158","article-title":"Development of CAR T cell therapy in children\u2014a comprehensive overview","volume":"11","author":"Boettcher","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.berh.2024.101976_bib186","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2024.101976_bib187","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2024.101976_bib188","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/annrheumdis-2022-eular.7","article-title":"POS0839 randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety OF SC abatacept in adults with active idiopathic inflammatory myopathy","volume":"81","author":"Aggarwal","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2024.101976_bib189","first-page":"474","article-title":"CD25 blockade for refractory polymyositis","volume":"31","author":"Pipitone","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2024.101976_bib190","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2024.101976_bib191","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.berh.2024.101976_bib192","series-title":"Depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM)","author":"Goel","year":"2021"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694224000470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694224000470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T03:34:03Z","timestamp":1727148843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694224000470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":191,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1521694224000470"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2024.101976","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2024.101976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101976"}}